Synovial tissue research: a state-of-the-art review (Q39431367)

11 September 2017

title

Synovial tissue research: a state-of-the-art review. (English)

1 reference

Corrigendum: Synovial tissue research: a state-of-the-art review

11 September 2017

corrigendum / erratum

0 references

author

Juan D Cañete

6

1 reference

11 September 2017

10

1 reference

11 September 2017

9

Paul Emery

0 references

Maya Hema Buch

4

Maya H Buch

0 references

Søren Andreas Just

Søren A Just

15

0 references

John D Isaacs

John D Isaacs

14

0 references

Anca Catrina

7

Anca I Catrina

1 reference

11 September 2017

25

Paul P Tak

1 reference

11 September 2017

Christopher D Buckley

5

Christopher D Buckley

1 reference

11 September 2017

Carl Orr

1

1 reference

11 September 2017

Elsa Sousa

2

1 reference

11 September 2017

David L Boyle

3

1 reference

11 September 2017

Ernest H S Choy

8

1 reference

11 September 2017

Andrew Filer

11

1 reference

11 September 2017

Danielle Gerlag

12

1 reference

11 September 2017

Frances Humby

13

1 reference

11 September 2017

Bernard R Lauwerys

16

1 reference

11 September 2017

Benoit Le Goff

17

1 reference

11 September 2017

Antonio Manzo

18

1 reference

11 September 2017

Trudy McGarry

19

1 reference

11 September 2017

Iain B McInnes

20

1 reference

11 September 2017

Aurélie Najm

21

1 reference

11 September 2017

Constantino Pitzalis

22

1 reference

11 September 2017

Arthur Pratt

23

1 reference

11 September 2017

Malcolm Smith

24

1 reference

11 September 2017

Rogier Thurlings

26

1 reference

11 September 2017

João E Fonseca

27

1 reference

11 September 2017

Douglas J Veale

28

1 reference

11 September 2017

language of work or name

English

0 references

publication date

13 July 2017

1 reference

Nature Reviews Rheumatology

11 September 2017

published in

1 reference

11 September 2017

volume

13

1 reference

11 September 2017

issue

8

1 reference

11 September 2017

page(s)

463-475

1 reference

The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Predicting mortality in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Key Challenges in Rheumatic and Musculoskeletal Disease Translational Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The secreted glycoprotein lubricin protects cartilage surfaces and inhibits synovial cell overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Interactive cytokine regulation of synoviocyte lubricant secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Cytokines in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Collagenase: a key enzyme in collagen turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The presence of citrullinated proteins is not specific for rheumatoid synovial tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Synovial tissue hypoxia and inflammation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Oxidative damage in synovial tissue is associated with in vivo hypoxic status in the arthritic joint.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Role of hyaluronic acid in joint lubrication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

A systems biology approach to synovial joint lubrication in health, injury, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Changes in lymphocyte infiltration of the synovial membrane and the clinical course of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Synovial tissue analysis for the discovery of diagnostic and prognostic biomarkers in patients with early arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

How to perform and analyse synovial biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Survey of arthroscopy performed by rheumatologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Ultrasound-guided synovial biopsy: a systematic review according to the OMERACT filter and recommendations for minimal reporting standards in clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Immunohistological features in the synovium obtained from clinically uninvolved knee joints of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Standardisation of synovial tissue infiltrate analysis: how far have we come? How much further do we need to go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Differential protein profiling of synovial fluid from rheumatoid arthritis and osteoarthritis patients using LC-MALDI TOF/TOF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Identification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Synovial biopsy in arthritis research: five years of concerted European collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Distinct synovial immunopathology in Behçet disease and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Of mice and men: how animal models advance our understanding of T-cell function in RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Ex-Th17 (Nonclassical Th1) Cells Are Functionally Distinct from Classical Th1 and Th17 Cells and Are Not Constrained by Regulatory T Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Immunopathogenesis of Rheumatoid Arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Asymptomatic synovitis precedes clinically manifest arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Joint-specific DNA methylation and transcriptome signatures in rheumatoid arthritis identify distinct pathogenic processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Epigenetically-driven anatomical diversity of synovial fibroblasts guides joint-specific fibroblast functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Clinical utility of the anti-CCP assay in patients with rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

IL-6-driven STAT signalling in circulating CD4 lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Signs of immune activation and local inflammation are present in the bronchial tissue of patients with untreated early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The cellular composition of lymph nodes in the earliest phase of inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

An imprinted rheumatoid arthritis methylome signature reflects pathogenic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Immunohistological analysis of synovial tissue for differential diagnosis in early arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Local synovial engagement of angiogenic TIE-2 is associated with the development of persistent erosive rheumatoid arthritis in patients with early arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Biomarkers for rheumatoid arthritis: making it personal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Ectopic lymphoid-like structures in infection, cancer and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Presence of lymphocyte aggregates in the synovium of patients with early arthritis in relationship to diagnosis and outcome: is it a constant feature over time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Chemokines in joint disease: the key to inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The role of S100A12 as a systemic marker of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Identification of rheumatoid arthritis and osteoarthritis patients by transcriptome-based rule set generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Identification of intra-group, inter-individual, and gene-specific variances in mRNA expression profiles in the rheumatoid arthritis synovial membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Selecting and validating biologic markers for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

From synovial tissue to peripheral blood: myeloid related protein 8/14 is a sensitive biomarker for effective treatment in early drug development in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Evaluation of gene expression measurements from commercial microarray platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

RNA-Seq: a revolutionary tool for transcriptomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Applications of targeted proteomics in systems biology and translational medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Does gene expression analysis inform us in rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Anti–tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Early changes in serum type ii collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-κB–dependent signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Acute serum amyloid A regulates cytoskeletal rearrangement, cell matrix interactions and promotes cell migration in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Survival, prognosis, and causes of death in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Permeability of Rheumatoid and Normal Human Synovium to Specific Plasma Proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Comparative distribution of proteins and glycoproteins of serum and synovial fluid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirt

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The diagnosis and prognosis of early arthritis: rationale for new prognostic criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRRHEUM.2017.115

Soluble biomarkers may differentiate psoriasis from psoriatic arthritis

31 March 2020

1 reference

12 December 2020

Synovial tissue analysis in clinical trials

1 reference

12 December 2020

Pro- and anti-inflammatory cytokines increase hyaluronan production by rat synovial membrane in vitro.

1 reference

12 December 2020

Joint erosions and patients with early rheumatoid arthritis

1 reference

12 December 2020

The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis

1 reference

12 December 2020

Variability in cytokine and cell adhesion molecule staining in arthroscopic synovial biopsies: quantification using color video image analysis

1 reference

12 December 2020

Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy

1 reference

12 December 2020

Intraarticular variability of synovial membrane histology, immunohistology, and cytokine mRNA expression in patients with rheumatoid arthritis.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2017.115

1 reference

Dimensions Publication ID

11 September 2017

Altmetric DOI

10.1038/NRRHEUM.2017.115

0 references

1090650879

0 references

1 reference